吲哚-4-硼酸 | 220465-43-0

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 吲哚-4-硼酸
• 中文别名: 1H-吲哚-4-基；4-吲哚硼酸
• 英文名称: indole-4-boronic acid
• 英文别名: (1H-indol-4-yl)boronic acid；(1H-indole-4-yl)boronic acid；1H-indol-4-ylboronic acid
• CAS: 220465-43-0
• 化学式: C₈H₈BNO₂
• mdl: MFCD03095175
• 分子量: 160.968
• InChiKey: USJUQEVUEBCLLR-UHFFFAOYSA-N

物化性质

• 沸点：
  433.2±37.0 °C(Predicted)
• 密度：
  1.33

计算性质

• 辛醇/水分配系数(LogP)：
  1.74
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• TSCA：
  N
• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S39
• 危险类别码：
  R37/38,R41,R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请保持冷静。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Indole-4-boronic acid
Synonyms: 4-Boronoindole; 4-Indoleboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Indole-4-boronic acid
CAS number: 220465-43-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BNO2
Molecular weight: 161.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吲哚-4-硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 甲苯 为溶剂， 反应 19.0h， 生成 (3-bromo-5-(1H-indol-4-yl)phenyl)(2-methyl-6-morpholinopyridin-4-yl)methanone
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of N-(3-(1H-Indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a Potent Antimitotic Agent

  摘要：

  The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald-Hartwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model

  DOI：

  10.1021/jm100659v
• 作为产物：
  描述：

  4-溴-1H-吲哚-3-羧酸甲酯 在 sodium hydroxide 、 叔丁基锂 、 potassium hydride 作用下， 以 甲醇 、 乙醚 、 正己烷 为溶剂， 反应 1.83h， 生成 吲哚-4-硼酸
  参考文献：
  名称：

  麦角酸的新合成。

  摘要：

  [反应：见正文]（+/-）-麦角酸是通过经济的8步路线由4-溴吲哚和异辛烯酸合成的，不需要在合成过程中保护吲哚。首先在环化步骤中未能成功形成较简单的3-acylindole衍生物，然后将其环化的初步努力。

  DOI：

  10.1021/ol0354369

文献信息

• [EN] ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH<br/>[FR] INHIBITEURS DE ASH1L ET MÉTHODES DE TRAITEMENT AU MOYEN DE CEUX-CI
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2017197240A1

  公开（公告）日：2017-11-16

  Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

  本文提供了ASH1L活性的小分子抑制剂，促进ASH1L降解的小分子以及它们的使用方法，用于治疗疾病，包括急性白血病、实体肿瘤和其他依赖于ASH1L活性的疾病。
• Copper-mediated 1,4-Conjugate Addition of Boronic Acids and Indoles to Vinylidenebisphosphonate leading to<i>gem</i>-Bisphosphonates as Potential Antiresorption Bone Drugs
  作者：Andrea Chiminazzo、Laura Sperni、Martina Damuzzo、Giorgio Strukul、Alessandro Scarso

  DOI：10.1002/cctc.201402346

  日期：2014.9

  wide range of gem‐bisphosphonate tetraethyl esters as precursors for bisphosphonic acids, which are potent inhibitors of bone resorption, bearing alkyl, aryl, and indole substituents in the β position were prepared through the CuII‐catalyzed 1,4‐conjugate addition of boronic acids and indoles to vinylidenebisphosphonate tetraethyl ester.

  宽范围的宝石通过将Cu制备-bisphosphonate四乙基酯作为二膦酸，它们是骨吸收的有效抑制剂，轴承烷基，芳基，且在β位的取代基的吲哚前体II催化的1,4-共轭加成的硼酸和吲哚为亚乙烯基双膦酸酯四乙酯。
• [EN] PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET D'INDOLE POUR LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2010073034A1

  公开（公告）日：2010-07-01

  There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for treating cancer.

  提供了式（I）的嘧啶基吲哚化合物，或其药用盐，其制备方法，含有它们的药物组合物以及它们在治疗中的应用，特别是用于治疗癌症。
• An approach to heterodiarylmethanes via sp2–sp3 Suzuki−Miyaura cross-coupling
  作者：Gavin W. Stewart、Peter E. Maligres、Carl A. Baxter、Ellyn M. Junker、Shane W. Krska、Jeremy P. Scott

  DOI：10.1016/j.tet.2016.02.030

  日期：2016.6

  The synthesis of a range of structurally diverse diarylmethanes via the Suzuki−Miyaura cross-coupling of aryl methane acetates and arylboronic acids is reported, including several challenging examples containing nitrogen, oxygen and sulfur heteroatoms in one or both coupling partners. A single set of optimized conditions was used to generate the diarylmethanes in 52–91% yield.

  据报道，通过芳基甲烷乙酸酯和芳基硼酸的Suzuki-Miyaura交叉偶联合成了一系列结构多样的二芳基甲烷，包括几个具有挑战性的例子，其中一个或两个偶联伙伴中都含有氮，氧和硫杂原子。一组优化的条件用于以52-91％的产率生成二芳基甲烷。
• Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
  作者：Xianming Deng、Barun Okram、Qiang Ding、Jianming Zhang、Yongmun Choi、Francisco J. Adrián、Amy Wojciechowski、Guobao Zhang、Jianwei Che、Badry Bursulaya、Sandra W. Cowan-Jacob、Gabriele Rummel、Taebo Sim、Nathanael S. Gray

  DOI：10.1021/jm100555f

  日期：2010.10.14

  Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based structure−activity

  伊马替尼对 Bcr-Abl 激酶活性的抑制用于治疗慢性粒细胞白血病 (CML)，目前作为用小分子靶向显性癌基因的范例。我们最近报道了 GNF-2 ( 1 ) 和 GNF-5 ( 2 ) 作为靶向肉豆蔻酸结合位点的细胞 Bcr-Abl 激酶活性的选择性非 ATP 竞争性抑制剂的发现。在这里，我们使用基于细胞的结构-活性关系来指导能够与肉豆蔻酸酯结合位点结合的配体的优化和多样化，并使基于 Abl-化合物1的发现合理化共晶。我们阐明了获得针对 Bcr-Abl 转化细胞的强效抗增殖活性所需的结构-活性关系，并报告了新化合物（5g、5h、6a、14d和21j-I）的发现，这些化合物显示出改进的效力或药理特性。这项工作表明，多种结构可以有效地靶向 Bcr-Abl 肉豆蔻酸酯结合位点，并为开发可靶向该结合位点的药物提供了新的线索。